SUNDAY, APRIL 29

MORNING, 10:00 AM – 1:00 PM

SC1: Preclinical and Clinical Assessment of Immunogenicity: Multidomain Therapeutics and New Modalities, Including Gene Therapy and CAR T
Beacon Hill 2&3

Detailed Agenda

Darshana Jani, MS, Senior Manager, Pfizer, Inc.
Seema Kumar, PhD, Associate Director, Quantitative Pharmacology & Drug Disposition (QPD), R&D Global Early Development (GED), EMD Serono, a business of Merck KGaA, Darmstadt, Germany
Magdalena Tary-Lehmann, MD, PhD, CSO, Cellular Technology Limited (CTL); Adjunct Associate Professor of Pathology, Case Western Reserve University (CWRU)
Ravi Shankar Singh, PhD, Associate Director, Clinical Pharmacology, Pfizer
Ben Hock, PhD, Director, Immunogenicity, BioMarin Pharmaceuticals
 

SC2: Translational Considerations for Development of Monoclonal Antibodies and Emerging Constructs: Part I: Focus on Construct Design
Beacon Hill 1

Detailed Agenda

Glareh Azadi, PhD, Senior Scientist, Translational PKPD, Merck Research Laboratories
Gadi Bornstein, PhD, Senior Director, Biologics Discovery, TESARO, Inc.
Veronica Juan, PhD, Principal Scientist, Protein Sciences, Merck Research Labs
Scott L. Klakamp, PhD, Senior Director, Head of Biophysics, Janssen R&D, LLC
Mohammad Tabrizi, PhD, Director Biologics Discovery, Merck Research Laboratories Palo Alto

SC4: Selection, Screening and Engineering for Affinity Reagents
Cambridge 1

Detailed Agenda

Jonas V. Schaefer, PhD, Lab Head/Investigator II, Novartis Institutes for BioMedical Research (NIBR)
Christian Kunz, PhD., Associate Director, MorphoSys AG

AFTERNOON, 2:00 – 5:00 PM

SC5: In silico Immunogenicity Predictions (Hands-On) Workshop
Cambridge 1

Detailed Agenda

Vinodh B. Kurella, PhD, Senior Scientist, Protein Engineering, Merrimack Pharmaceuticals
Eliud Oloo, PhD, Senior Principal Scientist, Schrodinger

SC6: Practical Considerations for Biomarker Bioanalysis
Cambridge 2

Detailed Agenda

Darshana Jani, Associate Director, Global Lead Biologics, Clinical Assay Group, Global Product Development, Pfizer
Paul Rhyne, PhD, Vice President, Biological Development Services
Stephanie Fraser, PhD, Associate Research Fellow, Pfizer
Tim Sikorski, PhD, Investigator, Exploratory Biomarkers, GlaxoSmithKline
Fizal Nabbie, PhD, Bristol-Meyers Squibb

SC7: Translational Considerations for Development of Monoclonal Antibodies and Emerging Constructs: Part 2: Focus on Preclinical Development
Beacon Hill 1

Detailed Agenda

Glareh Azadi, PhD, Senior Scientist, Translational PKPD, Merck Research Laboratories
Gadi Bornstein, PhD, Senior Director, Biologics Discovery, TESARO, Inc.
Veronica Juan, PhD, Principal Scientist, Protein Sciences, Merck Research Labs
Scott L. Klakamp, PhD, Senior Director, Head of Biophysics, Janssen R&D, LLC
Mohammad Tabrizi, PhD, Director, Biologics Discovery, Merck Research Laboratories Palo Alto

TUESDAY, MAY 1

DINNER, 6:00 – 8:30 PM

SC8: Introduction to Biophysical Analysis for Biotherapeutics: Discovery & Development Applications
Back Bay Complex

Detailed Agenda

Christine P. Chan, PhD, Principal Scientist, Global Manufacturing Science & Technology, Sanofi

SC9: CAR T Cell Therapy for Solid Tumors
Federal Complex

Detailed Agenda

Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School
Moonsoo M. Jin, PhD, Associate Professor, Molecular Imaging Innovations Institute, Radiology, Weill Cornell Medical College
Tara Arvedson, PhD, Director, Oncology Research, Amgen

THURSDAY, MAY 3

DINNER, 5:45 – 8:15 PM

SC10: Critical Considerations for the Design and Development of Antibody-Drug Conjugates
Federal Complex

Detailed Agenda

Isabel Figueroa, PhD, Scientist, PTPK, Genentech, Inc.
Shawn Owen, PhD, Assistant Professor, Pharmaceutics and Pharmaceutical Chemistry, University of Utah

SC11: Strategic/Modular Bioassay Design and Analysis
Washington

Detailed Agenda

David Lansky, PhD, President, Precision Bioassay, Inc.

SC13: Sub Visible Protein Particles in Immunogenicity: Measurement, Characterization and Impact
Back Bay Complex

Detailed Agenda

Björn Boll, PhD, Head, Particle Lab and Higher Order Structure Protein Analytics, Physical Chemical Analytics, Novartis Pharma AG
Anacelia Ríos Quiroz, PhD, Scientist, Group Leader Particle Lab, Pharma Technical Development Europe (Biologics) Analytics (PTDE-A), F. Hoffmann-La Roche Ltd.

DINNER, 5:45 – 8:45 PM

SC12: Transient Protein Production in Mammalian Cells
Skyline

Detailed Agenda

Richard Altman, MS, Scientist, Protein Technologies, Amgen
Henry C. Chiou, PhD, Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Bojiao Yin, PhD, Scientist, Protein Technologies, Amgen

2025 PROGRAMS

View By:

• Display of Biologics
• Engineering Antibodies
• Machine Learning for Protein Engineering

• Antibodies for Cancer Therapy
• Emerging Targets for Oncology & Beyond
• Driving Clinical Success in Antibody-Drug Conjugates

• TS: Intro to Multispecific Antibodies
• Advancing Multispecific Antibodies
• Engineering Bispecific and Multifunctional Antibodies

• Advances in Immunotherapy
• Engineering Cell Therapies
• Next-Generation Immunotherapies

• Difficult-to-Express Proteins
• Optimizing Protein Expression
• Maximizing Protein Production Workflows

• ML and Digital Integration in Biotherapeutic Analytics
• Biophysical Methods
• Characterization for Novel Biotherapeutics

• TS: Intro to Immunogenicity
• Predicting Immunogenicity with AI/ML Tools
• TS: Bioassay Development and Analysis

• Biologics for Immunology Indications
• Radiopharmaceutical Therapies
• Next-Generation Immunotherapies

• ML and Digital Integration in Biotherapeutic Analytics
• Predicting Immunogenicity with AI/ML Tools
• Machine Learning for Protein Engineering